Roche für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 851311 / ISIN: CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche Holding AG (Inhaberaktie)

10.09.24		Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (Roche Holding AG)
10.09.24		Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (GlobeNewswire)
10.09.24		Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen (GlobeNewswire)
04.09.24		Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis (Roche Holding AG)
04.09.24		Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis (GlobeNewswire)
27.08.24		Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH (Roche Holding AG)
27.08.24		Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH (GlobeNewswire)
20.08.24		Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak (Roche Holding AG)
20.08.24		Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak (GlobeNewswire)
30.07.24		European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) (Roche Holding AG)
30.07.24		European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) (GlobeNewswire)
29.07.24		Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care (Roche Holding AG)
29.07.24		Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care (GlobeNewswire)
25.07.24		[Ad-hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Halbjahr 2024 um 5% (CER); starkes Wachstum im zweiten Quartal – Gewinnprognose für das Gesamtjahr erhöht (GlobeNewswire)
25.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter - full-year earnings outlook raised (Roche Holding AG)
25.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised (GlobeNewswire)
18.07.24		New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions (GlobeNewswire)
18.07.24		New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions (Roche Holding AG)
17.07.24		Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study (GlobeNewswire)
17.07.24		Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study (Roche Holding AG)
17.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity (GlobeNewswire)
17.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity (Roche Holding AG)
09.07.24		Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes (Roche Holding AG)
09.07.24		Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes (GlobeNewswire)
08.07.24		Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) (Roche Holding AG)
08.07.24		Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) (GlobeNewswire)
05.07.24		FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss (Roche Holding AG)
05.07.24		FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss (GlobeNewswire)
04.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer (Roche Holding AG)
04.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer (GlobeNewswire)
28.06.24		Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) (GlobeNewswire)
28.06.24		Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) (Roche Holding AG)
28.06.24		CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition (Roche Holding AG)
28.06.24		CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition (GlobeNewswire)
27.06.24		Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection (Roche Holding AG)
27.06.24		Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection (GlobeNewswire)
25.06.24		Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis (Roche Holding AG)
25.06.24		Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis (GlobeNewswire)
24.06.24		Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories (Roche Holding AG)
24.06.24		Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories (GlobeNewswire)
20.06.24		Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma (GlobeNewswire)
20.06.24		Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma (Roche Holding AG)
15.06.24		Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
15.06.24		Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
10.06.24		Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization (Roche Holding AG)
10.06.24		Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization (GlobeNewswire)
10.06.24		European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer (Roche Holding AG)
10.06.24		European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer (GlobeNewswire)
07.06.24		Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk (Roche Holding AG)
07.06.24		Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk (GlobeNewswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Roche Peer Group Nachrichten

28.04.25		Ausblick: Pfizer legt Quartalsergebnis vor
28.04.25		Ausblick: Novartis mit Zahlen zum abgelaufenen Quartal
28.04.25		Merck-Aktie fester: Springworks für Milliardensumme übernommen
28.04.25		Bayer-Aktie schwächer: Neue Kurszielsenkung durch HSBC
28.04.25		Barclays Capital: Fresenius SE-Aktie erhält Overweight
28.04.25		Merck-Analyse: Merck-Aktie von Goldman Sachs Group Inc. mit Buy bewertet
28.04.25		Bernstein Research veröffentlicht Investment-Empfehlung: Merck-Aktie mit Market-Perform
28.04.25		Investment-Tipp: So bewertet Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) die Fresenius SE-Aktie

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	29.04.2025 06:02
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie

WKN: 851311 / ISIN: CH0012032113

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten